Can xiumeile, the first generic drug, still be the "best seller"?

In 2013, Humira's sales reached US $10.6 billion, ranking first among the top 25 best-selling drugs in 2013 Recently, India's imitator, Cadila, announced the launch of exemptia, the world's first imitator of Sumeria in India Cadila plans to set the price of exemptia as one fifth of that of Sumeria As soon as India's pharmaceutical companies sell, any high price will tremble! Can xiumeile's "best selling drug throne" be preserved? Exemptia is used to treat autoimmune diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis and ankylosing spondylitis, cadilla said The drug, which does not involve infringement of sumac's process and formula, is researched, developed and produced by scientists at zydus Research Centre According to the data, Sumeria's sales reached US $3.26 billion in the third quarter of 2014, accounting for 65% of the total revenue of abway In addition, in July, the FDA granted xiumeile orphan status in the treatment of noninfective middle, post or panuveitis or chronic noninfective anterior uveitis It is understood that Sumeria's US patent will expire in the second half of 2016 and European patent will expire in 2018 Sumeria's price in the U.S is $1000 a box, while cadilla plans to set the price of exemptia in the Indian market at $200 a box It's not a little cheap There are not a few who want to compete with xiumeile for the first place Sovaldi, the hepatitis C drug launched in 2013, had a sales volume of $2.27 billion in the first quarter of 2014 and a sales volume of $3.5 billion in the second quarter Analysts conservatively estimated that sovaldi could reach $15 billion in 2014 In addition, the list shows that the sales of lektronix and melowa, which are ranked second and third, have reached 9 billion in 2013 However, some analysts said that exemptia's market in India would not be too optimistic At present, 70% of India's population consumes less than $2 per day, and the $200 bottle of exemptia will be unaffordable for most Indians Cadilla estimates that exemptia's sales in the Indian market will reach US $16-32 million The drug is expected to launch in the U.S market in 2019.